Valneva has announced positive outcomes from its Phase III VLA1553-321 trial of the single-shot IXCHIQ chikungunya virus ...
Research by the authors on CHIKV is supported by NIH grants AI069145, AI082202, AI093491 and by a grant from the National Institute of Allergy and Infectious Disease (NIAID) through the Western ...
Hosted on MSN7d
Favorable VLA1553-321 Phase 3 Study Results Boost VALN StockValneva SE VALN, a specialty vaccine company, recently reported positive Phase 3 - VLA1553-321 data in adolescents (12 to 17 ...
Chikungunya is a disease that is caused by the chikungunya virus which is transmitted to humans by infected mosquitoes. Its name is derived from a word in the Makonde language that means contorted or ...
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further positive Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine, IXCHIQ ® ...
Valneva’s vaccine was highly immunogenic in both dose groups. A full dose of the vaccine exhibited a more robust immune response compared to a half dose by providing protective antibody titers already ...
Therefore a rapid, specific and sensitive test is necessary for effective surveillance of new CHIKV circulating strains. Moreover, no quantitative molecular tool has been described to study CHIKV ...
Valneva has announced positive outcomes from its Phase III VLA1553-321 trial of the single-shot IXCHIQ chikungunya virus (CHIKV) vaccine in adolescents. The trial demonstrated a ‘sustained ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback